Bacterial carbohydrates in neonatal sepsis: targets for immunotherapy.
Raff
H V
HV
Bristol-Myers Squibb, Pharmaceutical Research Institute, Seattle, WA 98121.
D000907:Antibodies, Bacterial / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000276:immunology*; D002241:Carbohydrates / Q000276:immunology*; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007231:Infant, Newborn; D018805:Sepsis / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D013290:Streptococcal Infections / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D013292:Streptococcus agalactiae / Q000276:immunology
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D002241:Carbohydrates; D016756:Immunoglobulins, Intravenous